• On 27 June 2026, Celcuity Inc. (NasdaqCM: CELC) was removed from multiple Russell indices, including the Russell 3000E, Russell 2000 Value, and Russell Microcap benchmarks, following the annual index reconstitution now in the past.
• This broad removal from Russell value and growth benchmarks may influence how index-tracking funds and active managers assess Celcuity’s visibility and liquidity profile.
• We’ll now consider how Celcuity’s broad removal from Russell indices could reshape the company’s investment narrative built around gedatolisib’s prospects.

The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Celcuity Investment Narrative Recap

To own Celcuity, you need to believe gedatolisib can convert its late stage breast cancer data and pending FDA decisions into a first commercial franchise, while the company manages heavy cash burn and debt. The broad Russell index removals may affect trading liquidity and some passive ownership, but they do not alter the core near term catalyst around July 2026 regulatory milestones, nor the key risk that clinical or regulatory outcomes fall short of expectations.

The most relevant recent announcement here is Celcuity’s June 4, 2026 upsized US$500 million convertible note offering, which adds to an already leveraged balance sheet. This extra financing supports ongoing trial work and launch build out around VIKTORIA 1 and VIKTORIA 2, but, in combination with index removal, it also sharpens the focus on dilution, interest costs and the company’s need to translate gedatolisib’s clinical profile into meaningful revenue.

However, investors should be aware that if revenue ramps slower than expected, the mix of index removal, higher cash burn and growing debt obligations could...

Celcuity's narrative projects $817.9 million revenue and $267.5 million earnings by 2029. This implies an earnings increase of about $460 million from -$192.9 million today.

Uncover how Celcuity's forecasts yield a $161.09 fair value, a 48% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already expecting only about US$414.4 million of revenue and US$129.7 million of earnings by 2029, so you should weigh whether broad index removal and funding needs strengthen that more cautious view or leave meaningful upside if gedatolisib delivers closer to the consensus case.

Explore 4 other fair value estimates on Celcuity - why the stock might be worth over 8x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Celcuity research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Celcuity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Celcuity's overall financial health at a glance.

Seeking Other Investments?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• Find 44 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.